Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)

NCT03541174 is registered in ClinicalTrials.gov with Idorsia Pharmaceuticals Ltd. as lead sponsor.

NCT NCT03541174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03541174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Phase
Phase 3
Overall status
Completed
Start date
June 18, 2018
Completion date
April 25, 2022
Enrollment
730 (actual)
Sites
159

Conditions

As the registry lists them; a condition with its own page is linked.

resistant hypertension